New Products

Jun 14, 2017

OmniSeq Immune Report Card

OmniSeq has launched its Immune Report Card, an immune profiling test designed to help oncologists select the best mono and combination immunotherapy options for patients. The assay integrates five clinical-grade tests that together provide a comprehensive immune profile. The report card includes CD3/8 and PD-L1 immunohistochemistry, PD-L1/2 copy number using in situ hybridization, microsatellite instability testing, mutational burden analysis via Thermo Fisher Scientific's Ion Torrent next-generation sequencing of 409 exon cancer genes, and cross-validated simultaneous gene expression analysis of 54 critical transcripts via targeted RNA-seq using the Oncomine Immune Response Research Assay. The test is approved by the New York State Clinical Laboratory Evaluation Program, the company said.

Jun 12, 2017

DNA Software PanelPlex

DNA Software has released PanelPlex, a cloud-based product designed to aid with multiplexing of molecular diagnostics for infectious disease. Customers may use the product directly through cloud computing, or may opt to have DNA Software conduct design work using the product. Features of the product include automated assay design for a particular species among a panel of its variants and its near neighbors; wet-lab-validated results; and inclusivity and exclusivity "panels" for diagnostic quality design, according to the company's website.

Jun 07, 2017

Prevention Genetics Tests for Female, Male Infertility

Prevention Genetics has launched genetic tests for both female and male infertility. The new infertility sequencing panels cover 83 genes for females and 80 genes for males. They also include chromosomal microarray, Y chromosome deletion testing, and FMR1 CGG repeat expansion for premature ovarian failure. Tests must be ordered through a qualified health provider and will be performed in the company's CLIA- and ISO 15189:2013-accredited laboratory.

Jun 07, 2017

Cytek Biosciences Aurora Flow Cytometry System

Cytek Biosciences has launched its Aurora advanced flow cytometry system. The multiparametric system is capable of detecting more than 20 colors using three excitation lasers and 50 channels. It has the ability to detect any fluorescence emission in the 400-900 nm range without having to change optical filters, depending on the laser excitation wavelength, the company said. Aurora's optical design and unmixing algorithm enables the use of a wide array of dyes, including those with highly overlapping spectra.

Jun 07, 2017

Thermo Fisher Scientific Q Exactive HF-X Hybrid Quadrupole Orbitrap MS

Thermo Fisher Scientific has launched its Q Exactive HF-X Hybrid Quadrupole Orbitrap mass spectrometer. The new MS platform delivers mass analysis with two- to three-fold sensitivity improvements while delivering the same number of protein identifications in half the time required for previous models. It also provides up to eight times better signal-to-noise ratio for native, intact monoclonal antibody mass determination, glycoprofiling, and purity checks. For more on Thermo Fisher's new platform click here.

Jun 02, 2017

Phosphorus Hereditary Cancer Panels

Phosphorus has released new advanced tests for hereditary cancers. The tests are organized into three panels — a common/high-risk panel comprising 32 genes that interrogates "the most actionable and widely-recognized genes across cancer types"; a 114-gene pan cancer panel; and disease-specific panels covering 11 specialties, including breast; colorectal; brain/nervous system; leukemia; pancreatic; ovarian/uterine; renal; thyroid; melanoma; prostate; and pediatric cancer. 

Jun 02, 2017

Centogene Noninvasive Prenatal Testing

Centogene has launched its CenoNIPT test for noninvasive prenatal testing. The test uses Illumina VeriSeq NIPT Solution. It is performed on a single maternal blood sample and combines the latest next-generation sequencing technology with the highest quality medical reporting. The company's optimized workflows allows patients to receive a full medical report within five working days.

Jun 02, 2017

NeoGenomics Immuno-Oncology Profiling Tests

NeoGenomics has launched an expansion of its NeoTYPE cancer profiles to include Tumor Mutation Burden (TMB) and microsatellite instability (MSI) testing. TMB is a new genomic biomarker that is designed to predict response to checkpoint inhibitor immunotherapies targeting the PD-1 and PD-L1 proteins. The TMB tests will be available on a standalone basis, and in combination with the various cancer-specific NewTYPE tests, the company said. MSI testing will be offered to patients to identify metastatic solid tumors that are MSI-high or mismatch repair deficient (MMR). They company is offering MSI testing as a result of the FDA's recent approval of Merck's Keytruda drug to treat patients identified to have MSI-high or MMR tumors.

Jun 02, 2017

Desktop Genetics DTG-Seq Service

Desktop Genetics recently launched its DTG-Seq service, which combines targeted amplicon sequencing and internal bioinformatics expertise for validation of on- and off-target genome editing outcomes. To use DTG-Seq, customers send isolated genomic DNA samples to Desktop's sequencing provider, while Desktop handles steps such as primer design and amplicon library preparation. The company's bioinformatics team then analyzes raw FASTQ files and investigates the efficiency and distribution of CRISPR mutations at on- and/or off-target sites. Desktop then summarizes and delivers the analysis in graphical reports along with raw sequencing data files. The company said that it can detect CRISPR editing events at frequencies as low as 0.1 percent.

May 31, 2017

New England Biolabs NEBNext Ultra II RNA Library Prep Kits

New England Biolabs has launched an expansion of its NEBNext Ultra II NGS library preparation portfolio with the NEBNext Ultra II Directional RNA Library Prep kit and the non-directional NEBNext Ultra II RNA Library Prep kit. Both kits are designed for Illumina's next generation sequencing systems and are compatible with poly(A) mRNA isolation and ribosomal RNA depletion. Libraries can be constructed from a substantially broader input range (5 ng to 1 µg of total RNA) at high yields. They also use workflows that include new reagents, combined steps, and minimized cleanup steps.

May 30, 2017

Sophia Genetics Whole Exome Solution, Clinical Exome Solution

Sophia Genetics launched the Whole Exome Solution and Clinical Exome Solution for the detection of disease-related genetic variants. The two solutions use AI technology to give clinicians a better understanding of genomic data for more accurate and personalized clinical care, the firm said. 

May 26, 2017

Biomatters Geneious Biologics Software

New Zealand-based Biomatters has introduced Geneious Biologics, an enterprise software platform to support development of biologic drugs. The technology helps biotechnology and biopharma companies manage and analyze genomic data from multiple sources in the name of identifying potential antibodies. Biomatters has built an API into Geneious Biologics to facilitate integration into existing IT systems.

May 26, 2017

Eagle Genomics EagleCurate

Eagle Genomics has launched EagleCurate, a product designed to automate the time-consuming process of data curation. EagleCurate combines data measurement with machine learning to create graphical representations of experimental processes, study designs, observational studies, assays, and other elements that biocurators and statisticians often struggle with.

May 26, 2017

Horizon BRAF-Resistant Melanoma PDX Models

Horizon Discovery has launched four new BRAF-resistant melanoma patient derived xenograft (PDX) models. The company has partnered with the Wistar Institute of Anatomy and Biology in Philadelphia to make their melanoma PDX models available to the research community. The models are created by implanting cancerous tissued from a human primary tumor directly into immunodeficient mouse or rat models.They can support drug efficacy studies, the company said.

May 25, 2017

GATC Biotech OncoPanel All-In-One

GATC Biotech has launched the OncoPanel All-in-One, a cancer gene panel for liquid biopsy and tissue biopsy samples. The next-generation sequencing panel enables the accurate detection of clinically actionable mutations and structural rearrangements for solid tumors, including lung, colon, breast, ovarian, melanoma, and gastrointestinal tumors. It covers the exons of 597 genes and selected promoter regions to identify clinically relevant mutations, including single nucleotide polymorphisms, insertions and deletions, copy number variations, and gene fusion events.

May 24, 2017

Strata Oncology StrataNGS

Strata Oncology has launched StrataNGS, a 90-gene targeted next-generation sequencing assay that focuses on actionable genetic alterations in tumor tissue. The test has a 10-day turnaround time and analyzes both DNA and RNA from either fresh or archival biopsy tissue.  

May 24, 2017

Interpace TERT biomarker

Interpace Diagnostics launched the TERT biomarker for ordering along with its ThyGenX molecular thyroid cancer test. The TERT marker is a molecular predictor of the aggressiveness of thyroid cancer, and the addition of it to the ThyGenX test will provide evidence that a positive result indicates the cancer is likely to be more aggressive in nature, the company said. Physicians can order the new marker as part of the ThyGenx mutation panel or on an individual basis. 

May 24, 2017

AM Biotechnologies X-Aptamer Selection Kit

AM Biotechnologies has launched the X-Aptamer Selection Kit for the in-lab discovery of X-Aptamers, next-generation aptamers that feature amino acid and small-molecule functionality attached to DNA bases and selectively bind to antigens with high affinity. The kit features a combinatorial bead-based library employing a single-round process for the discovery of X-Aptamers. The process takes less than a week, including sample preparation, requires no special lab equipment or procedures, and enables the discovery of X-Aptamers for up to five targets in parallel per kit. The introductory price for the kit is $500.

May 24, 2017

Thermo Fisher Scientific Ion AmpliSeq On-Demand

Thermo Fisher Scientific has launched Ion AmpliSeq On-Demand, customizable targeted next-generation sequencing panels for inherited disease research. Customers design panels using the Ion AmpliSeq Designer tool. They can search for and add their genes of interest to the panel or use the designer tool's disease-gene database to search for relevant genes by the disease.

May 23, 2017

Biocartis IVD NRAS Test for Colorectal Cancer

Biocartis has launched its Idylla NRAS Mutation Test. The CE-marked IVD assay joins the company's existing Idylla NRAS-BRAF Mutation Test, allowing for more flexibility in geographies where BRAF testing for metastatic colorectal cancer patients is not reimbursed. According to Biocartis, the NRAS-only assay detects 18 mutations directly from a single slice of FFPE tumor tissue in approximately two hours, with less than two minutes hands-on time.
May 22, 2017

Phase Genomics ProxiMeta Hi-C

Phase Genomics has launched ProxiMeta Hi-C, a service that employs Hi-C sequencing on metagenomic samples to obtain complete individual genomes without culturing or high molecular weight DNA extraction. ProxiMeta Hi-C is based on capturing DNA with in vivo Hi-C so sequence reads can be traced back to their cell of origin. Researchers from the University of Washington first described the approach in 2014 in G3: Genes Genomes Genetics.

May 18, 2017

PrimBio Exome Data Analysis

PrimBio Research Institute has launched new exome data analysis services. The service uses generated VCFs from sequenced exomes or aligned BAM files to provide exome data analysis. The company can provide consumers with QC filtered exome data sets, variant classification, molecular function of a variant, determining drug resistance or drug efficacy, using in silico tools, reporting clinical trial information of clinically significant variants, and complete references associated with findings, the company said.

May 18, 2017

Saphetor Variant Analysis Platform v.5.4

Saphetor has launched the newest version of its Variant Analysis Platform, v.5.4. The updated version has improved variant classification in line with American College of Medical Genetics and Genomics guidelines. It also includes more annotations, such as gnomAD exomes and updated and curated Clinvar data, an improved upload process, and improved read alignment interface for multi-sample analyses.

May 17, 2017

Synthego Online CRISPR Tools

Synthego has released online CRISPR tools that make more than 100,000 genomes accessible for gene knockout guide design. The tools include a guide designer, a design validator, and the ability to order CRISPR guide RNA. Researchers can select a desired gene of interest from a curated list of genomes representing more than 9,000 species. The Synthego tool then uses several built-in algorithms to instantly generate guide designs and recommendations for the most efficient guides with low off-target effects and highest likelihood to knock out the function of a gene, the firm said. Additional features include the ability to validate, share, and purchase synthetic single guide RNA. The new tools are free to use and available at design.synthego.com.

May 17, 2017

Claritas Genomics HLH/MAS Region of Interest Test

Claritas Genomics has launched the Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS) Region of Interest test to its menu of exome-based molecular diagnostic testing. The test encompases 20 genes relevant to autosomal recessive or x-linked primary HLH and auto-inflammatory disease that can trigger MAS. It also identifies variants in exons and adjacent intronic sequences and detects deep intronic variants in UNC13D. The assay uses the company's dual-capture, dual sequencing platform method.

Pages

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.